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Neuropeptide Y (NPY) is a unique peptide with wide 
distribution in central and peripheral nervous systems. 
In the guinea pig, NPY-positive fibers are prominent in 
the myenteric plexus. To test whether NPY inhibits 
myenteric plexus acetylcholine (ACh) release and to de- 
fine mechanisms, a purified preparation of myenteric 
plexus neurons was derived from the teniae coli of neo- 
natal guinea pigs and maintained in primary culture. 
Incubation of cultured neurons labeled with [SH]ACh in 
the presence of NPY ( 10-14-10-6 M) significantly inhib- 
ited basal ACh release (83 + 16 to 58 +- 11% of control). 
NPY significantly inhibited ACh release stimulated by 
potassium (55 m&f); by adenylate cyclase agonists fors- 
kolin (lo-’ M) and cholera toxin (lo-’ M); and by calci- 
tonin gene-related peptide, cholecystokinin octapep- 
tide, and vasoactive intestinal peptide (each lo-‘M). In 
each instance, the inhibitory effects of NPY were re- 
versed by preincubation with pertussis toxin. Reversal 
of inhibitory effects by pertussis toxin suggests that the 
actions of NPY are mediated via an inhibitory GTP- 
binding protein. Q 1991 Academic Press, Inc. 
INTRODUCTION 
Neuropeptide Y (NPY) is a unique 37 amino acid pep- 
tide that was first isolated from the porcine brain [l]. 
The peptide, with expression restricted to neurons, is 
widely distributed in both the central and peripheral 
nervous systems [2-41. NPY has strong amino acid se- 
quence homology with pancreatic polypeptide (PP) and 
peptide YY (PYY); the three compose a family of regula- 
tory peptides [5,6]. Pancreatic polypeptide immunoreac- 
tivity is found in endocrine cells of the pancreatic islets 
[7]. PYY immunoreactive cells have been localized 
within the mucosa of the gastrointestinal tract, espe- 
cially the distal small intestine [S]. Within the digestive 
tract, NPY-positive neurons are found in the stomach, 
the intestine, and both the endocrine and exocrine por- 
tions of the pancreas [9, lo]. 
1 This study was supported by National Institutes of Health Grant 
DK 40633. 
In the guinea pig intestine, NPY -positive nerve fibers 
constitute approximately 5% of all neurons within the 
myenteric plexus (11). The gut contains both extrinsi- 
cally and intrinsically derived NPY -positive neurons; 
extrinsic NPY nerve fibers have been reported to con- 
tain adrenergic neurotransmitters, the majority originat- 
ing from postganglionic sympathetic neurons [12, 131. 
However, denervation experiments in rats indicate the 
largest number of the NPY-positive fibers are intramu- 
ral in origin [ 141. Intrinsic NPY -immunoreactive nerve 
fibers are believed to be nonadrenergic [ 131. Intrinsic 
NPY -positive myenteric plexus neurons also stain posi- 
tively for vasoactive intestinal polypeptide and peptide 
histidine isoleucine (PHI) [ 15,161. This combination of 
anatomic findings suggests that NPY may have impor- 
tant actions on enteric neuronal activity. 
Garzon and associates have reported that NPY re- 
duces the resting tension of guinea pig longitudinal mus- 
cle strips [17]. NPY was also noted to reduce the excit- 
atory effects of cholecystokinin octapeptide via a neur- 
ally mediated mechanism [ 171. Close arterial infusion of 
NPY in the cat produces inhibition of colonic motility; 
the effect is not mediated by adrenergic receptors [18]. 
While the physiologic relevance of these actions of NPY 
within the myenteric plexus remains to be established, 
they suggest that the peptide may exert inhibitory ac- 
tions upon enteric neurons. 
The current investigation was performed to test the 
hypothesis that NPY inhibits release of acetylcholine 
from enteric neurons and to study the mechanism by 
which such an inhibitory action might be exerted. The 
studies were designed to directly test the ability of NPY 
to modulate acetylcholine release by using cultured 
myenteric plexus neurons. The involvement of neuronal 
adenylate cyclase in the activity of NPY was determined 
and the potential role of GTP-binding proteins in the 
observed effects was examined. 
MATERIALS AND METHODS 
Materials. The following chemicals were purchased: 
hemicholinium, collagenase, penicillin, streptomycin, 
veratridine, forskolin, Sbromo cyclic AMP, cholera 
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toxin, pertussis toxin, poly-L-lysine (Sigma Chemical, 
St. Louis, MO), vasoactive intestinal peptide (VIP), 
substance P, calcitonin gene-related peptide (CGRP), 
cholecystokinin octapeptide (CCK-8) (Peninsula Labs, 
Belmont, CA), Medium 199, (GIBCO, Grand Island, 
NY), and Nu-Serum (Collaborative Research, Bedford, 
MA). Neonatal Duncan-Hartley guinea pigs were pur- 
chased from Simonsen Labs (Gilroy, CA). Tritiated cho- 
line and tritiated acetylcholine were obtained from New 
England Nuclear (Boston, MA). 
Myenteric plexus neuronal culture. Primary culture 
of myenteric plexus neurons was accomplished by an 
adaptation of previously described methods [19, 201. 
Neonatal Duncan-Hartley guinea pigs were sacrificed, 
and using aseptic technique, the longitudinal smooth 
muscle of the teniae coli was dissected from the cecum; 
care was exercised not to enter the lumen of the bowel. 
Teniae coli were divided into 5- to 6-mm segments and 
were transferred to a Petri dish containing Hanks’ bal- 
anced salt solution (HBSS) with highly purified collage- 
nase (1 mg/ml) and incubated at 37°C for 1.25-1.5 hr. 
Tissue fragments were then transferred to fresh HBSS 
where, under a dissecting microscope, loosely adherent 
smooth muscle cells were dissected from the myenteric 
plexus, producing a purified myenteric plexus prepara- 
tion [21]. Cell viability was maintained up to 21 days in 
culture. 
The tissues derived from each animal were divided 
into 12 segments (approximately lo5 cells per segment). 
Isolated plexuses were explanted into tissue culture 
wells previously coated with poly-L-lysine (10 pg/ml). 
Plexuses were exposed to culture medium containing 
Medium 199 supplemented with nonessential amino 
acids, Na-pyruvate, Hepes buffer (1 M), and L-gluta- 
mate (200 mM) plus NU-Serum (lo%), glucose (5 mg/ 
ml), and penicillin-streptomycin solution (100 U/ml). 
Culture medium was exchanged every second day and 
antibiotics were omitted after the initial feeding. Acetyl- 
choline release studies were performed after 5 to 7 days 
in culture. Cultured plexuses were used for study only if 
they were firmly adherent to the culture well and exhib- 
ited extensive outgrowth of dendritic processes. Each 
plexus culture was inspected for the presence of uniform 
neuronal growth. 
Acetylcholine release studies. The release of [3H]- 
labeled acetylcholine ( [3H]ACh) was studied after expo- 
sure of neurons to [3H]choline (0.2 /IM, specific activity 
80 Ci/mmole) in oxygenated modified Krebs-Ringer 
buffer containing 50 PM physostigmine. Incubation with 
[3H]choline was carried out at 37°C for 60 min in a Dub- 
noff metabolic incubator gassed with 95% O,-5% CO,. 
Tissues were then washed twice with fresh buffer and 
allowed to recover for 30 min before exposure to ago- 
nists. 
Each neuronal aggregate was exposed to only one test 
condition. Plexuses were exposed to NPY for 30 min 
before addition of agonists in those experiments utiliz- 
ing coincubation with a test peptide. In experiments em- 
ploying pertussis toxin, neurons were coincubated with 
the toxin for 18 hr prior to addition of agonists. 
In all experiments, total 3H was determined to indi- 
cate transmitter release. Labeled neurons were washed 
and then exposed to agonists in a release medium con- 
taining the following constituents: NaCl, 118 mM, KCl, 
4.7 mM; NaHPO,, 1 mM, MgCl,, .0.5 mM; CaCl,, 2.5 
mM; NaHCO,, 25 &, glucose, 11.1 mM; physostig- 
mine, 50 PM and hemicholinium, 10 FM. NaCl was ad- 
justed to maintain osmolarity. Labeled neurons were ex- 
posed to agonists in this release medium for 15 min; the 
release medium was then aspirated and added to scintil- 
lation fluid. The remaining tissue was solubilized and 
then placed in scintillation fluid. Radioactivity was 
quantified by liquid scintillation spectrometry. [3H]ACh 
was expressed as the percentage of total tissue 3H re- 
leased into the medium. 
In order to verify that the 3H released was ACh, col- 
umn chromatography was used. After stimulation with 
the respective agonists, aliquots of release medium were 
applied to a cation exchange resin (Bio-Rex 70) to sepa- 
rate [3H]ACh and [3H]choline from other products. Un- 
labeled ACh and choline were applied to the column 
along with [14C]ACh as a marker for ACh. The column 
was eluted with NaHPO, buffer and radioactivity was 
determined. Two peaks of radioactivity were observed 
and greater than 90% of the increase in 3H occurring 
after stimulation was in the form of [3H]ACh. 
Data analysis. Fractional release was calculated by 
expressing the radioactivity in the release medium as the 
percentage of total radioactivity in the tissue at the time 
of the experiment. The percent release of t3H]ACh over 
basal was calculating by dividing the fractional release 
produced by agonists by the spontaneous (basal) release. 
All results were expressed as group means f SEM. Each 
experiment was performed using the tissues derived 
from one animal; the sample size (n value) was taken as 
the number of guinea pigs; all experimental groups had n 
values of 6 to 8. Statistical analysis was performed using 
one-way analysis of variance. Significance was accepted 
as P < 0.05. 
RESULTS 
Effects of NPY on basal ACh release. To determine if 
NPY inhibits basal ACh release from cultured myen- 
teric plexus neurons, we examined the effects of the pep- 
tide on 13H]ACh release from unstimulated neuronal 
plexuses. Neurons were exposed to varying concentra- 
tion of NPY for 15 min in release medium to which no 
agonists had been added. Mean 15-min basal release was 
4.5 -t 0.2% in the absence of NPY. Basal release of 
[3H]ACh was significantly suppressed (68 -+ 10% of con- 
trol) by exposure of plexuses to NPY at concentrations 
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FIG. 1. Effect of NPY on basal [3H]ACh release from cultured 
myenteric plexus neurons. [3H]ACh-labeled neurons (n = 6 animals) 
were exposed to release medium in the absence or presence of graded 
concentrations of NPY for 15 min. [sH]ACh release was quantified as 
the percentage released into the medium relative to the total con- 
tained within the tissue at the beginning of the experiment. *P < 0.05 
vs control. 
as low as lo-l4 M (Fig. 1). Statistically significant inhibi- 
tory effects were observed at each of the NPY concen- 
trations employed except 10-l’ M. 
Effects of NPY on stimulated ACh release. Pre- 
liminary studies were performed to determine respon- 
siveness of cultured neurons in terms of [3H]ACh release 
to various agonists. Exposure to potassium (55 mM) 
caused significant increases in [3H]ACh release (261 f 
47% of basal). Dose-dependent increases in [3H]ACh re- 
lease were noted with exposure to the depolarizing agent 
veratridine, with maximal stimulation noted at lop6 M 
(342 + 67%). Incubation with the cyclic AMP agonists 
forskolin, cholera toxin (CTX), or B-bromo cyclic AMP 
was, in each instance, associated with dose-related in- 
creases in labeled ACh release. Exposure to peptide neu- 
rotransmitters was also associated with dose-related in- 
creases in [3H]ACh release. Incubation with CGRP or 
CCK-8 (10 nm) produced increases in [3H]ACh release 
of 73 + 33% and 82 f 28% above basal values, respec- 
tively. Substance P exposure dose-dependently in- 
creased [3H]ACh release (179 + 62% at 10 nm), as did 
VIP (10 nm incubation: 227 f 49% of basal). Dose-re- 
sponse data were used to calculate ED,, values for each 
agonist. Submaximal agonist concentrations, for use in 
subsequent combination with NPY, were chosen based 
upon these agonist dose-response studies. 
To investigate potential inhibitory effects of NPY on 
stimulated ACh release, we coincubated NPY with the 
above agonists. In experiments using NPY, the peptide 
(lo-’ M) was added to the release medium 15 min before 
exposure to agonist. To investigate the possibility that 
NPY antagonizes stimulated ACh release via activation 
of inhibitory (Gi) regulatory proteins, in some experi- 
ments we exposed neurons to pertussis toxin (PTX) 
prior to addition of NPY and agonists. Pertussis toxin 
has been demonstrated to ribosylate the Gi protein and 
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FIG. 2. Effects of NPY on potassium and veratridine-stimulated 
[3H]ACh release. Labeled neurons were exposed to potassium (55 
n&f) or to veratridine (10-s M) in release medium. NPY (lo-* M) was 
added 15 min prior to exposure to agonists. In experiments utilizing 
PTX (100 rig/ml), toxin was added to culture medium 18 hr prior to 
exposure to agonists. *P < 0.05 vs control. 
ing this mechanism. Pertussis toxin (100 rig/ml) was 
added 18 hr prior to [3H]choline exposure. 
NPY produced significant suppression of potassium- 
stimulated [3H]ACh release (190 f 36% of basal) (Fig. 
2). The inhibitory effects of NPY on potassium-stimu- 
lated [3H]ACh release were reversed by preincubation 
with PTX (304 f 71%). Veratridine-stimulated (lo-* iU) 
[3H]ACh was modestly decreased after exposure to NPY 
(from 144 + 5% to 119 +- 10%); the difference did not 
achieve statistical significance, however (Fig. 2). 
[3H]ACh release stimulated by forskolin ( low6 M) was 
abolished by preincubation with NPY (260 f 79% vs 84 
f 14%). The inhibitory effects of NPY were reversed by 
PTX pretreatment (Fig. 3). Similarly, NPY inhibited 
ACh release stimulated by CTX, decreasing fractional 
[3H]ACh release from 212 + 52% to 72 + 10% of basal. 
PTX pretreatment reversed NPY inhibition of CTX ef- 
fects (152 & 12%). In contrast to the effects observed 
with forskolin or CTX, stimulation of [3H]ACh release 
by B-bromo cyclic AMP was not affected by NPY 
(Fig. 3). 
In the last group of experiments, the ability of NPY to 
inhibit neuropeptide-stimulated ACh release was tested 
s 400 
5 IT n Agonist alone 0 6l Agonist+NPY 








Forskolin CTX 8-Br-CAMP 
FIG. 3. Effects of NPY on [aH]ACh release stimulated by CAMP 
agonists. Labeled plexuses were stimulated by forskolin (lo-‘M), chol- 
era toxin (CTX: 10m8 M), or 8-bromo cyclic AMP (10-s M). In accom- 
panying wells, neurons were exposed to agonist plus NPY (10-s M) or 
to NPY after preincubation with PTX. *P < 0.05 vs control. 
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FIG. 4. Effects of NPY on neuropeptide-stimulated [3H]ACh re- 
lease. Cultured neurons were exposed to CGRP, CCK-8, VIP, or sub- 
stance P (10-s M) alone, or with NPY (10-s M), or with NPY after 
PTX preincubation (n = 8). *P < 0.05 vs control. 
(Fig. 4). NPY significantly inhibited CGRP-stimulated 
[3H]ACh release (209 f 31% vs 120 f 9%); the inhibitory 
effects were reversed by PTX preexposure (205 + 29%). 
CCK-B-stimulated ACh release (192 + 28% of basal) was 
significantly diminished by NPY coincubation (110 
-t 13%); PTX preincubation reversed the inhibitory ef- 
fects. Similarly, VIP stimulation of [3H]ACh release was 
suppressed by NPY exposure (227 f 49% vs 130 -+ 12%), 
and the inhibitory effects were reversible with PTX pre- 
treatment. In contrast, [3H]ACh release stimulated by 
substance P was not inhibited by NPY coincubation. 
DISCUSSION 
This study has clearly demonstrated that NPY in- 
hibits the release of ACh from cultured guinea pig myen- 
teric plexus neurons. NPY was observed to suppress ba- 
sal release of [3H]ACh at concentrations as low as lo-l4 
M, indicating both its potent inhibitory effects and the 
sensitivity of the neurons in culture to respond to exoge- 
nous peptides. NPY was also noted to inhibit [3H]ACh 
release stimulated by potassium-induced depolarization 
and by a variety of cholinergic secretagogues. 
In preliminary studies, forskolin, cholera toxin, and 
B-bromo cyclic AMP were each shown to stimulate 
[3H]ACh release from myenteric plexus neurons, con- 
firming previous reports that agents which raise intra- 
cellular CAMP levels stimulate the release of ACh from 
the myenteric plexus [22]. NPY was observed to inhibit 
the effects of forskolin, an agent which stimulates ade- 
nylate cyclase activity and the effects of CTX, an agent 
that activates adenylate cyclase indirectly through ef- 
fects on stimulatory GTP-binding proteins [23, 241. In 
contrast, [3H]ACh release stimulated by B-bromo 
CAMP, a soluble congener of CAMP, was not affected by 
NPY exposure. The ability of B-bromo CAMP to mimic 
increased intracellular CAMP levels does not depend 
upon activation of adenylate cyclase. These observa- 
tions, taken together, suggest that NPY inhibits cholin- 
ergic transmission in the myenteric plexus by inhibiting 
neuronal adenylate cyclase and preventing accumula- 
tion of intracellular CAMP. In support of this mecha- 
nism, NPY has recently been reported to inhibit forsko- 
lin-stimulated CAMP accumulation in the nucleus trac- 
tus solitarius region of the rat brain [25]. 
NPY was also demonstrated to inhibit ACh release 
stimulated by CGRP, CCK-8, or by VIP; the magnitude 
of the inhibitory effects were similar (approximately 
45%) for each of the peptide agonists. Recent reports 
provide indirect evidence that intracellular CAMP accu- 
mulation may mediate ACh release from myenteric neu- 
rons caused by each of these peptides. CGRP has been 
reported to stimulate ACh release from myenteric 
plexus neurons. The release occurs via a mechanism that 
is sensitive to 2’,5’-dideoxyadenosine [26]. Dideoxyade- 
nosine has been shown to inhibit neuronal adenylate cy- 
clase and to block the accumulation of intracellular 
CAMP. The ability of VIP to increase ACh release from 
myenteric plexus neurons is also sensitive to dideoxy- 
adenosine, indicating activity via neuronal adenylate 
cyclase [27]. In addition, electrophysiological studies us- 
ing myenteric plexus neurons have demonstrated that 
VIP and CCK-8 generate slow excitatory postsynaptic 
potentials, a pattern characteristically associated with 
cholinergic depolarization [28, 291. The generation of 
slow excitatory postsynaptic potentials can be blocked 
by adenosine. The ability of NPY to inhibit [3H]ACh 
release stimulated by CGRP, CCK-8, or VIP demon- 
strated in the current investigations is thus consistent 
with a mechanism involving inhibition of adenylate cy- 
clase. In contrast, NPY was not noted to inhibit 
[3H]ACh release stimulated by substance P. The effects 
of substance P are not mediated, in myenteric plexus 
neurons, via effects on intracellular CAMP. 
The inhibitory actions of NPY on [3H]ACh release 
were pertussis toxin sensitive. Guanine nucleotide-bind- 
ing proteins have been demonstrated in a number of sys- 
tems that couple inhibitory receptors to membrane- 
bound adenylate cyclase [30]. Such regulatory compo- 
nents (Gi) are sensitive to ADP-ribosylation catalyzed 
by pertussis toxin; exposure to pertussis toxin inacti- 
vates Gi and prevents inhibitory peptides from decreas- 
ing adenylate cyclase activity. The reversal of NPY inhi- 
bition of forskolin- and CTX-stimulated [3H]ACh re- 
lease by PTX pretreatment strongly suggests G protein 
involvement in the observed actions. PTX sensitivity of 
NPY inhibition of ACh release stimulated by CGRP, 
CCK-8, and VIP provides further support for the in- 
volvement of G, protein in the actions of NPY in myen- 
teric plexus neurons. Wiley and co-workers have demon- 
strated that an inhibitory guanine nucleotide-binding 
protein mediates NPY inhibition of ACh release from 
nodose ganglion neurons [31]. Additionally, in myen- 
teric plexus neurons, inhibition of ACh release by so- 
matostatin has also been shown to be PTX-sensitive 
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[22]. G protein mediation of adenylate cyclase activity, 
demonstrated in this study for NPY, may serve as a 
mechanism by which a variety of inhibitory neurotrans- 
mitters or hormones regulate cholinergic transmission 
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